Clinical Trials on Atypia Suspicious for Malignancy in South Africa

Total 228 results

Novartis

Completed

A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis

Atopic Eczema

South Africa
BioGaia AB

Completed

Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis

Atopic Dermatitis

South Africa
Red Cross War Memorial Childrens Hospital

Completed

Accessible and Affordable Moisturizers for Atopic Eczema

Childhood Atopic Dermatitis

South Africa
Bayer

Completed

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

Atopic Dermatitis

South Africa
Bayer

Completed

HPA Axis Study in Adults

Eczema | Atopic Dermatitis

South Africa
DS Biopharma

Completed

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Atopic Dermatitis

United States, South Africa
Red Cross War Memorial Childrens Hospital

Unknown

Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis.

Severe Atopic Dermatitis

South Africa
DS Biopharma

Completed

Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Atopic Dermatitis

United States, Canada, South Africa
Cosmetique Active International

Recruiting

Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis

Skin Diseases | Atopic Dermatitis

Croatia, Germany, Portugal, South Africa, Taiwan, Thailand, Vietnam
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.

Atopic Dermatitis

South Africa, Belgium, Germany, Australia, Netherlands, Bulgaria, Austria, Romania
Akeso

Not yet recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114

Metastasis | Advanced or Metastatic Solid Tumors | Malignancy

Australia
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield; Sheffield Children's NHS Foundation Trust

Completed

Skin Pathology Assessment With Optical Technologies (SPOT)

Atopic Dermatitis Eczema

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

Skin bioMARkers for Atopic Eczema Therapy Evaluation (SMART)

Atopic Eczema/Dermatitis (Non-Specific)

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Active, not recruiting

A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study (STAR)

Atopic Eczema

United Kingdom
Spartanburg Regional Family Medicine

Unknown

Evaluation of Topical B12 for the Treatment of Childhood Atopic Dermatitis

Eczema

United States
Biosion, Inc.
Southern Star Research Pty Ltd.

Completed

Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis

Atopic Dermatitis

Australia
Hoth Therapeutics, Inc.
Novotech (Australia) Pty Limited

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Application of Topical BioLexa in Adult Healthy Subjects and Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Australia
Clinical Research Center of the Carolinas
Pfizer

Completed

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

Atopic Dermatitis

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia
Vyne Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

Atopic Dermatitis

United States, Australia
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
Nanjing Immunophage Biotech Co., Ltd
Novotech (Australia) Pty Limited

Not yet recruiting

A Study of Orally Administered IPG7236 in Healthy Adult Participants

Atopic Dermatitis

Australia
Murdoch Childrens Research Institute

Active, not recruiting

Micronised Resveratrol as a Treatment for Friedreich Ataxia

Friedreich Ataxia

Australia
Pfizer

Completed

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Dermatitis, Atopic

Australia
Akesobio Australia Pty Ltd

Recruiting

Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Australia, New Zealand
Sanofi

Recruiting

A Study to Assess the Reliability/Feasibility of Using Emerald Touchless Sensor for Scratching and Sleep Quantification in a Subset of Participants From PEDISTAD Study (OBS15333; NCT03687359)

Dermatitis Atopic

United States
HanAll BioPharma Co., Ltd.

Completed

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Mild to Moderate Atopic Dermatitis

United States
Arcutis Biotherapeutics, Inc.

Completed

Pharmacokinetics (PK), Safety, Efficacy and Maximal Use PK of ARQ-151 in Adolescents/Children With Mild/Moderate Eczema

Atopic Dermatitis (Eczema)

United States
Hill Dermaceuticals, Inc.
Covance; Synteract, Inc.

Terminated

Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Piramal Enterprises Limited
Melanoma Research Foundation Breakthrough Consortium

Suspended

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

Advanced or Inoperable Malignant Melanoma With BRAF Mutation

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis (NEURADAD)

Moderate-to-severe Atopic Dermatitis

United States
Fougera Pharmaceuticals Inc.

Completed

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

Psoriasis | Atopic Dermatitis

United States
Anesiva, Inc.

Completed

Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
BioMimetix JV, LLC
Innovaderm Research Inc.

Terminated

A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
Amgen

Active, not recruiting

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Arena Pharmaceuticals

Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis (ADVISE)

Atopic Dermatitis

United States, Australia, Canada
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Regeneron Pharmaceuticals
Sanofi

Recruiting

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial (DISCOVER)

Moderate-to-Severe Atopic Dermatitis | Atopic Eczema

United States
LEO Pharma

Completed

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Atopic Dermatitis

United States, France, Netherlands
Nestlé

Completed

Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis

Atopic Dermatitis

Taiwan
ASLAN Pharmaceuticals

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

Atopic Dermatitis

Australia, Singapore, United States
Australian & New Zealand Children's Haematology...
National Health and Medical Research Council, Australia; Secura Bio, Inc.

Terminated

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT (NORTH)

Rhabdoid Tumor | Atypical Teratoid/Rhabdoid Tumor | Malignant Rhabdoid Tumor | Recurrent Brain Tumor, Childhood

Australia, New Zealand, United States
Siolta Therapeutics, Inc.

Active, not recruiting

Allergic Disease Onset Prevention Study (adored)

Atopic Dermatitis | Type 1 Hypersensitivity

United States, Australia, Puerto Rico
Escient Pharmaceuticals, Inc

Recruiting

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis (EASE)

Atopic Dermatitis

United States, Canada
Dermavant Sciences, Inc.

Completed

Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Ralexar Therapeutics, Inc.

Unknown

Study in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis Eczema

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Germany, New Zealand, Australia
BioMimetix JV, LLC

Completed

Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Psoriasis | Atopic Dermatitis

United States
Pfizer

Completed

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)

Dermatitis, Atopic

United States, Hungary, Canada, Germany, Australia, Czechia, Poland, United Kingdom

Clinical Trials on Atypia Suspicious for Malignancy in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations